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Abstract
Substituted 1H-pyrazolo[3,4-b]pyridine-4- and 1H-pyrazolo[3,4-b]pyridine-6-carboxamides have been synthetized through a
Doebner–Ugi multicomponent reaction sequence in a convergent and versatile manner using diversity generation strategies: combi-
nation of two multicomponent reactions and conditions-based divergence strategy. The target products contain as pharmacophores
pyrazolopyridine and peptidomimetic moieties with four points of diversity introduced from readily available starting materials in-
cluding scaffold diversity. A small focused compound library of 23 Ugi products was created and screened for antibacterial activity.
Introduction
Modern medicinal chemistry is faced with the task of quick and
effective screening a variety of organic molecules in order to
identify new active pharmaceutical ingredients among them.
Therefore, in turn, organic chemistry has to solve an equally im-
portant task of the rapid generating focused libraries of drug-
like compounds characterized by several important features,
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Scheme 1: An overview of heterocyclic acids used in the Ugi reaction.
e.g., molecular complexity and diversity at different levels, high
variability and easy accessibility from relatively simple
reagents. These challenges can be overcome by using multi-
component reactions (MCRs) but also other strategies can be
applied in addition to MCRs for generating diversity, e.g.,
build/couple/pair- (BCP), single reactant replacement- (SRR),
modular reaction sequences- (MRS), conditions-based diver-
gence- (CBD) and combination of multicomponent reactions
(MCR2) strategies (for more details and examples see [1-3] and
Scheme 1). A synergetic application of several diversity-
oriented synthesis (DOS) instruments allows an effective deco-
ration of the privileged scaffolds for creating collections of
unique, highly potent bioactive compounds [4,5].
The pyrazolopyridine scaffold can be regarded as a privileged
motif as it exhibits various biological actions: antiproliferative
[6-9], antimicrobial [10,11], anxiolytic [12], analgesic [13],
hypnotic [13], antiviral [13], anti-HIV [13] activities, etc.
Soural et al. [14] explored different data and showed the rele-
vance of compounds composed of two or more heterocyclic
rings for drug discovery. The target products containing a
heterocyclic core bound to a peptide-like chain also showed a
broad spectrum of biological activity: β-secretase (BACE1)
inhibitory activity [15]; inducing apoptosis in colorectal cancer
cells [16]; antimalarial activity against a chloroquine (CQ) non-
resistant Plasmodium falciparum 3D7 strain [17]; antagonists of
p53-Mdm2 interaction [18]; antiproliferative activity in the
human solid tumor cell lines A549 (lung), HBL-100 (breast),
HeLa (cervix), SW1573 (lung), T-47D (breast), and
WiDr(colon) [19]; cyclophilin A inhibitory activity for the treat-
ment of hepatitis C virus infections [20], etc.
Among the variety of heterocyclic acids used in Ugi-4CR [15-
19,21-42] only a few of them in addition to bearing a simple
pharmacophore core (group I, Scheme 1) are also characterized
by the complexity and diversity of the skeleton itself gained
through multi-step transformations (group II) [18,19,34-36] or
allow for generating additional diversity through post-cycliza-
tion reactions (group III) [18,35-42]. Meanwhile the complexi-
ty of the acid skeleton can be achieved by MCR. Several publi-
cations illustrated this principle: synthesis of heterocyclic acids
[26,43] or enols [44] in a first multicomponent step, followed
by subjecting them to a subsequent Ugi process, thus, applying
the MCR2 approach (group IV, Scheme 1).
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Scheme 2: Synthesis of pyrazolopyridine carboxylic acids 4 [45] and 7 [45] in Doebner-type reaction.
Actually, there was no example for the combined application of
Doebner and Ugi-type MCRs although the former condensation
easily affords the azoloazine pharmacophore that is able to
participate as an acid component in the latter reaction. It should
be noted, that Cowen et al. [6] reported N-substituted-1H-pyra-
zolo[3,4-b]pyridine-4-carboxamides being SMYD2 inhibitors
(an oncogenic methyltransferase that represses the functional
activity of the tumor suppressor proteins p53 and RB); the simi-
lar structures can be obtained using the methodology of sequen-
tial Doebner- and Ugi-type MCRs.
In the present work we combined several diversity-oriented syn-
thetic (DOS) approaches. First, by using CBD and MCR strate-
gies in a Doebner-type reaction we synthesized pyrazolopyri-
dine carboxylic acids which were subsequently applied in the
Ugi reaction, thus, combining two multicomponent procedures.
Results and Discussion
As mentioned above, the diversification of the privileged scaf-
fold using different DOS strategies allowed to significantly
increase the diversity of the final products. In our study pyra-
zolo[3,4-b]pyridine scaffold was chosen as a privileged one and
based on this, we combined two MCRs: the previously well-
studied three-component Doebner-type condensation of
aminopyrazoles, aldehydes and pyruvic acid [45,46] with the
isocyanide-based four-component Ugi reaction.
As we have shown before [47,48] the application of the CBD
strategy to multicomponent Doebner-type condensations in-
volving aminoazoles allowed the synthesis of several chemo-
types of structurally complex products from a limited number of
relatively simple starting materials just by varying the reaction
conditions (temperature, solvent–catalyst system, activation
method, forced realization of one of the cascades of multicom-
ponent treatment). We decided to use this strategy and to
synthetize heteroaromatic carboxylic acids 4 and 7 starting from
the same reactants but using a multicomponent and a sequential
protocol. We chose these heterocyclic acids to be subjected to
the further Ugi transformation based on their higher stability
compared to other azoloazine carboxylic acids (e.g., tetrahydro-
[49,50] and dihydroazoloazines that may undergo oxidation
during the Ugi 4CR) and as they do not contain additional func-
tional groups that may influence the subsequent Ugi reaction
(e.g., hydroxy group in tetrahydro- [46,51], dihydro- [51] or ar-
omatic derivatives [51]).
Two different reaction pathways were applied based on known
synthetic procedures (Scheme 2): the three-component reaction
between pyruvic acid (1), aromatic aldehydes 2a,b and
5-amino-3-methylpyrazole (3) (HOAc, Δ, 30 min) [45] and a
two-component condensation of the preliminary synthetized
4-(4-methoxyphenyl)-2-oxobut-3-enoic acid (5b) [52,53] with
5-amino-3-methyl-N-phenylpyrazole (6) (HOAc, Δ, 5 h). As a
result, two different types of pyrazolo[3,4-b]pyridines contain-
ing the carboxylic group either at C4 position (compounds 4a,b)
or at the C6 position (compound 7b) were synthetized
(Scheme 2). We modified the earlier described methodology for
the synthesis of pyrazolo[3,4-b]pyridine-6-carboxylic acid (7b)
[45]: the solvent was changed from DMF to HOAc and the
reaction time was increased from 30 min to 5 hours. Despite of
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the longer reaction time the whole procedure became more effi-
cient due to the easier work-up stage as well as due to avoiding
the formation of impurities of the dihydropyrazolo[3,4-
b]pyridines.
Thus, starting from the same set of reactants two different types
of heterocyclic acids 4 and 7 containing two diversity points
were obtained. Afterwards compounds 4a,b were introduced
into the Ugi four-component reaction to create 3 additional
points of diversity. However, due to the low solubility of the
pyrazolopyridine acids 4a,b under the literature standard reac-
tion conditions for the Ugi transformation (stirring in methanol
at rt and similar procedures) the reaction did not take place.
Under these conditions, the pyrazolopyridine carboxylic acids
4a,b did not dissolve and remained unreacted even after
prolonged stirring and heating. Consequently, the solvent was
changed to DMF that allowed us to isolate the Ugi products 11
after long stirring (48–72 h) at rt. It must be noted, that in many
cases the pyrazolopyridine acids 4a,b did not fully dissolve in
DMF at rt that resulted in considerably decreased yields.
In an attempt to increase the yield of the products the reaction
was repeated at different temperatures ranging from rt to 80 °C
and it was found that heating at 70 °C afforded the best results.
At this temperature not only the yields increased but also the
reaction time could be reduced to 48 hours. When applying a
solvent mixture of DMF and MeOH the yields further in-
creased, with the best results obtained using a ratio of 1:2. We
presume that methanol provides the optimal acidity to the reac-
tion medium needed for successful protonation of the intermedi-
ate azomethine, formed between the aromatic aldehyde 8 and
aniline 9, to the corresponding iminium cation and its further
transformation involving carboxylic acid 4 and isocyanide 10.
As a result, we developed an efficient procedure for the synthe-
sis of compounds 11a–q through reaction of aromatic alde-
hydes 8a–d, amines 9a–f, tert-butylisocyanide (10) and
heteroaromatic carboxylic acids 4a,b in a 2:1 mixture of metha-
nol and DMF at 70 °C. Following this procedure, a small library
of seventeen Ugi products was obtained (Table 1).
Next, we applied pyrazolo[3,4-b]pyridine-6-carboxylic acid 7b
with another positional location of the substituents in compari-
son with compounds 4 in the Ugi reaction with the same
reagents 8, 9 and 10 using the optimized procedure (Table 1).
This expanded the library of Ugi products by adding com-
pounds 12a–f.
The purity and structures of the obtained heterocyclic products
were established by means of NMR spectroscopy, mass spec-
trometry, and elemental analysis. The final assignment of the
structures 11 and 12 was made by X-ray analysis for the struc-
ture 11n (Figure 1).
Figure 1: Molecular structure of N-(2-(tert-butylamino)-1-(4-chloro-
phenyl)-2-oxoethyl)-6-(4-methoxyphenyl)-3-methyl-N-p-tolyl-1H-pyra-
zolo[3,4-b]pyridine-4-carboxamide (11n) according to X-ray diffraction
data. Non-hydrogen atoms are presented as thermal ellipsoids with
50% probability.
Antibacterial activity
It is worth mentioning that the modification of the pyrazolo[3,4-
b]pyridine scaffold through Ugi reaction allowed not only to
introduce three additional diversity points but also to increase
significantly the solubility of the products 11 and 12 compared
to the starting acids 4 and 7. Compounds 11 are soluble in
MeOH, EtOH, iPrOH, acetone, EtOAc, CH3CN, DCM, CHCl3
and compounds 12 are soluble in acetone, CH3CN, DCM,
CHCl3 and partially soluble when heated in EtOAc, MeOH,
EtOH, showing the advantages of this protocol for investigat-
ing the activity of pyrazolo[3,4-b]pyridine moiety in biological
experiments. Particularly, the evaluation of the antibacterial ac-
tivity of the small library of new compounds 11 and 12 was
carried out.
We next screened some selected compounds for their antibacte-
rial activity (Table 2, Supporting Information File 1) against the
reference bacterial strains Bacillus subtilis (strain 1211),
Staphylococcus aureus (strain 2231) (gram-positive) and
Escherichia coli (strain 1257), Pseudomonas aeruginosa (strain
1111) (gram-negative).
Generally, the compounds were found to be less active than
nitroxoline being the reference substance. The results obtained
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Table 1: Synthesis of compounds 11 and 12 by combination of Doebner and Ugi-type MCRs.
Starting materials Products
Entry Acid R1 8 R2 9 R3 11,12 yield, %
1 4a H 8a H 9a H 11a 39
2 4a H 8a H 9b 4-CH3 11b 40
3 4a H 8a H 9c 4-Br 11c 30
4 4a H 8a H 9d 2-CH3O 11d 28
5 4a H 8a H 9e 3-CH3O 11e 30
6 4a H 8a H 9f 4-CH3O 11f 42
7 4b CH3O 8a H 9a H 11g 43
8 4b CH3O 8a H 9b 4-CH3 11h 53
9 4b CH3O 8a H 9c 4-Br 11i 37
10 4b CH3O 8a H 9d 2-CH3O 11j 37
11 4b CH3O 8a H 9e 3-CH3O 11k 35
12 4b CH3O 8a H 9f 4-CH3O 11l 42
13 4b CH3O 8b Cl 9a H 11m 44
14 4b CH3O 8b Cl 9b 4-CH3 11n 49
15 4b CH3O 8b Cl 9c 4-Br 11o 34
16 4b CH3O 8b Cl 9f 4-CH3O 11p 37
17 4b CH3O 8c NO2 9a H 11q 20
18 7b CH3O 8a H 9a H 12a 50
19 7b CH3O 8a H 9b 4-CH3 12b 51
20 7b CH3O 8b Cl 9a H 12c 34
21 7b CH3O 8b Cl 9b 4-CH3 12d 36
22 7b CH3O 8d CH3O 9a H 12e 46
23 7b CH3O 8d CH3O 9b 4-CH3 12f 25
indicate that some substances inhibited the growth of the test
microorganisms demonstrating weak antimicrobial effect
(Table 2). The growth of gram-positive bacteria (strains of
S. aureus and B. subtilis) was inhibited in a more effective way.
Particularly, compound 11b inhibited the growth of B. subtilis
at a concentration of 125 mg/L. A bacteriostatic activity against
S. aureus was observed only at the higher concentrations of 250
and 500 mg/L. The same situation was found for the tested E.
coli strain. The gram-negative bacterium P. aeruginosa showed
resistance to all compounds tested in the given concentration
range. The observed low level of antibacterial activity of
the synthesized heterocycles is a good prerequisite for
screening them for other types of activity, e.g., anticancer,
antidiabetic, etc., because in these cases a negative
influence on the microflora of the organism would be de-
creased [54].
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Table 2: Antibacterial activity results.
Entry Compound MICa/MBCb,
mg/L






1 11a MIC 250 –c 250 250
MBC – – – –
2 11b MIC 500 – 500 125
MBC – – – –
3 11f MIC – – – –
MBC – – – –
4 11g MIC 250 – – 250
MBC – – – –
5 11l MIC – – – –
MBC – – – –
6 11m MIC 500 – 250 250
MBC – – – –
7 nitroxoline MIC 15.6 62.5 31.25 1.9
MBC 15.6 62.5 31.25 1.9
aMIC – minimum inhibitory concentration; bMBC – minimum bactericidal concentration; cthe substance at concentration ≤ 500 mg/L does not inhibit
culture growth.
Conclusion
In summary, two multicomponent reactions of Doebner and
Ugi-type were combined in a convergent and versatile manner
giving substituted 1H-pyrazolo[3,4-b]pyridine-4- and 1H-pyra-
zolo[3,4-b]pyridine-6-carboxamides. The use of a conditions-
based divergence strategy allowed introducing the scaffold
diversity and obtaining two types of structures with different
orientation of substituents (containing a carboxylic group either
at C4 or C6 position of the pyrazolopyridine core). The optimal
methodology for the synthesis of target products was elabo-
rated (mixture of methanol and DMF (2:1) and heating to
70 °C) and a small focused library of 23 Ugi products was
created. The target compounds containing two pharmacophore
pyrazolopyridine and peptidomimetic moieties were screened
for their antibacterial activity and demonstrated weak antibacte-
rial effect.
Supporting Information
Supporting Information File 1
Experimental and analytical data.
[https://www.beilstein-journals.org/bjoc/content/
supplementary/1860-5397-15-126-S1.pdf]
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